COX-2 signaling and cancer: new players in old arena
Shashank Misra, Kulbhushan Sharma1
1Division of Radiation Biosciences, Institute of Nuclear Medicine and Allied Sciences (INMAS), Brig. S.K. Mazumdar Marg, Timar Pur, Delhi 110054, India. kulsinmas@gmail.com.
Abstract:
Cancer is a leading cause of death worldwide. The expression of COX-2 and prostaglandins has not only been associated with various types of cancer but is also directly proportional to their aggressiveness including metastasis. Thus, inhibition of COX-2 activity has been one of the preferred targets for cancer reduction. Broad spectrum inhibition of all forms of COX (using NSAIDs) is associated with various side effects ranging from gastric ulceration to renal problems. Even specific COX-2 inhibitors (COXIBs) are associated with side effects like myocardial infarction. Alternative strategies including siRNA technology are also not very victorious due to their off-target associated problems. Thus, there is an urgent need for the development of strategies where COX-2 activity may be reduced without inducing any side effects. One of the approaches for designing novel inhibitors may be to target various molecules downstream of COX-2. In this review, we have tried to cover the basic biology of COX-2 and its association with different types of cancer. Various generations of COX-2 inhibitors have been covered with their merits and demerits. Possible exploitation of novel targets like EP receptors, mPGES and various other downstream molecules which can be utilized for a better COX-2 signaling inhibition and thus efficient cancer reduction with minimal side effects has been discussed.
Insights
Targeting cyclooxygenase-2 (COX-2) is crucial for cancer treatment. This review explores novel strategies to inhibit COX-2 signaling and reduce cancer progression with fewer side effects.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cyclooxygenase-2 (COX-2) and prostaglandins are linked to cancer aggressiveness and metastasis.
- Current COX-2 inhibitors (NSAIDs, COXIBs) and siRNA have significant side effects or limitations.
- There is a critical need for safer strategies to inhibit COX-2 activity in cancer.
Purpose of the Study:
- To review the fundamental biology of COX-2 and its role in various cancers.
- To analyze the advantages and disadvantages of different generations of COX-2 inhibitors.
- To explore novel therapeutic targets downstream of COX-2 for effective cancer reduction with minimal adverse effects.
Main Methods:
- Comprehensive literature review of COX-2 biology and cancer association.
- Analysis of existing COX-2 inhibitors, including NSAIDs and COXIBs.
- Exploration of emerging therapeutic targets such as EP receptors and mPGES.
Main Results:
- COX-2 expression correlates with cancer severity and metastatic potential.
- Conventional COX-2 inhibition strategies present significant safety concerns.
- Targeting downstream molecules offers a promising avenue for safer cancer therapy.
Conclusions:
- Developing novel COX-2 inhibitors that target downstream molecules is essential for effective cancer treatment.
- Exploiting targets like EP receptors and mPGES can lead to improved cancer reduction strategies.
- Future research should focus on minimizing side effects while maximizing therapeutic benefits in cancer therapy.
More Related Videos
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes